Edmundo Brito-de la Fuente from Fresenius Kabi Deutschland has published the following study: ‘Determination of dissolution profile and bioaccessibility of Ketosteril using an advanced gastrointestinal in vitro model’ in a recent edition of Dissolution Technologies.
For this study the TIM-1 model was set-up to specifically mimic conditions resembling patients with chronic kidney disease. Importantly, TIM-1 provided highly reproducible results that significantly outperformed classic dissolution methods regarding the predicted in vivo situation. In addition, this work shows the use of TIM technology in studying pathophysiological conditions, highlighting its use in studying human gastrointestinal behavior of compounds in health and disease.
For more information, please contact:
Business Development Manager
M +31 6 52803578
Triskelion B.V. has signed a new research collaboration contract with Lesaffre. At the core of the collaboration is the so-called TIM system, a dynamic in vitro model of the stomach and small intestine developed by Triskelion. This innovative system will enable Lesaffre to study and validate the effectiveness of its existing products or develop new solutions for the future.
About 25 years ago TNO (now Triskelion) started the development of the “TIM” systems, TNO Intestinal Models. TIM are computer controlled models that realistically simulate processes that occur during the digestion of compounds. In contrast to static digestion models and methods, TIM is a dynamic simulation of gastrointestinal processes, based on in vivo data. This makes it highly predictive for the human situation (> 80%) and it can be considered the most advanced digestion model.
TIM is used by academia and industry to advance research on the behavior of orally ingested compounds, such as foodstuffs, functional ingredients or orally ingested pharmaceutical drug products, and their interactions with each other. Researching orally ingested compounds in vitro shortens product development time and ultimately time to market. TIM users even report fewer animal studies, because these can be replaced by TIM experiments.
As a global key player in yeasts and fermentation, Lesaffre designs, manufactures and markets innovative solutions for Baking, Food taste & pleasure, Health care and Biotechnology. For many years Lesaffre has been relying on its fermentation expertise to develop innovative solutions for its customers. With 570 experts and 10 Research centers around the world, innovation is at the heart of its development and Lesaffre is today focused on providing new solutions to tomorrow’s nutrition and health challenges.
“With this partnership with Triskelion, we are proud to combine leading technology platforms, such as TIM, with our scientific knowledge on microorganisms and ingredients derived from fermentation. This collaboration will contribute to accelerate the development of health benefit products, such as probiotics, in a sustainable way,” says Carmen Arruda, R&D director at Lesaffre.
Geneesmiddel onderzoek moet sneller, beter voorspellend en reproduceerbaar zijn. Het gebruik van dieren is regelmatig onvoldoende betrouwbaar en geeft vaak een afwijkend resultaat ten opzicht van humane condities. Het Triskelion model “TIM” bootst het humane maag- darm kanaal na en levert een betrouwbaar resultaat.
Hierover lees je meer in het magazine BiotechNews & LifeSciences – May 2019.
Pharmaceutical Research needs to be faster, more predictive and reproducible. The predicted data value out of laboratory animal research is continuously under discussion and in many cases insufficient to decide upon.
The Triskelion “TIM” model mimics the human gastro intestinal tract in a more predictable, reproducible, fast and controllable manner.
You can read the full article in the Dutch online magazine “BiotechNews & LifeScience – May 2019”.
We are happy to invest in a call to translate and explain the full content of this outing.
Please contact us: email@example.com or +31 652803578
Proud to announce the involvement of our experts in next weeks workshop: Global Food Contact on the 14th – 16th of May 2019 in Lisbon, Portugal.
Devasena’s white paper on ‘Risk assessment of Non-Intentionally Added Substances in Food Contact Materials’ is available and just one click away.
Dennis is a speaker at the Pre-Conference Workshop: ‘NIAS Challenges, Hurdles & Possible Solutions’ on Tuesday the 14th of May 2019 | 12.45-16:00h.
Dennis or Devasena would be pleased to meet you in Lisbon. Please contact us to make an appointment upfront: firstname.lastname@example.org.